Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4256984 · 3 trials · 2 indications
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4256984 | EXPERIMENTAL | LY4256984 administered intrathecally (IT) |
| LY4256984 (Cohorts 1-4) | EXPERIMENTAL | Multiple ascending doses (MAD) of LY4256984 administered intrathecally (IT) |
| Placebo | PLACEBO_COMPARATOR | Administered IT |
| Name | Type | Description |
|---|---|---|
| LY4256984 | DRUG | Administered IT |
| Placebo | DRUG | Administered IT |
Participants must meet eligibility criteria in the \[L0U-MC-OLMP\] screening protocol before entry into the treatment study. Inclusion Criteria: * Have completed the main treatment period/phase as well as any off-treatment period/phase of Study OWAA, the parent study for this ISA. Exclusion Crite...
LY4256984 is an investigational small molecule being developed for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It is currently in Phase 1 clinical trials for sporadic ALS, which is the most common form of the disease.
LY4256984 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and tolerability in participants with sporadic ALS.
LY4256984 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is currently being studied in early-stage trials to assess its safety, tolerability, and pharmacokinetics in participants with sporadic ALS.
LY4256984 is being studied in three Phase 1 clinical trials: NCT07100119, a study in participants with sporadic ALS; NCT07571174, a substudy in participants with sporadic ALS; and NCT07571200, a master protocol study in participants with ALS. All trials are currently recruiting participants.
No alternative names for LY4256984 have been disclosed. The drug is identified solely by its compound number LY4256984 in clinical trial registrations and scientific literature. It is a distinct investigational small molecule being developed by Eli Lilly and Company for ALS.
The LY4256984 clinical trials are randomized, double-blind, and placebo-controlled. Each of the three Phase 1 studies plans to enroll 32 participants, for a total of 96 participants across the trials. The studies are recruiting adults aged 18 years and older in Belgium, Canada, Germany, Netherlands, and Spain.